<p>Travere Therapeutics, Inc.（納斯達克代碼：TVTX - 獲取免費報告）首席執行官 Eric Dube 於 1 月 23 日（星期五）出售了 8,135 股公司股票。股票的平均售價為 30.01 美元，總交易額為 244,131.35 美元。交易完成後，首席執行官持有公司 419,173 股股票，價值為 12,579,381.73 美元。此次交易代表其持股比例減少了 1.90%。該交易已在向美國證券交易委員會（SEC）的備案中披露，相關信息可通過此鏈接獲取。</p>
<p>獲取 <strong>Travere Therapeutics</strong> 的提醒：</p>
<h2>Travere Therapeutics 價格表現</h2>
<ul>
<li>3 家不為人知的醫療公司</li>
</ul>
<p>在週二的午盤交易中，納斯達克：TVTX 上漲 0.09 美元，達到 30.03 美元。公司股票交易量為 1,424,711 股，而其平均交易量為 2,922,582 股。Travere Therapeutics, Inc. 的一年最低價為 12.91 美元，一年最高價為 42.13 美元。該公司的債務與股本比率為 4.23，流動比率為 2.75，速動比率為 2.71。該公司的 50 日簡單移動平均線為 34.58 美元，200 日簡單移動平均線為 27.12 美元。</p>
<p>Travere Therapeutics（納斯達克：TVTX - 獲取免費報告）最近於 10 月 30 日（星期四）公佈了其財報。公司報告本季度每股收益（EPS）為 0.28 美元，超出分析師一致預期的（0.31 美元）0.59 美元。Travere Therapeutics 的淨利潤率為-20.32%，股本回報率為-178.68%。該公司本季度的收入為 1.6486 億美元，而分析師預期為 1.0609 億美元。去年同期，該公司的每股收益為（0.70 美元）。與去年同期相比，該公司的收入增長了 162.1%。分析師預測 Travere Therapeutics, Inc.在當前年度的每股收益將為-1.4 美元。</p>
<h2>機構投資者對 Travere Therapeutics 的看法</h2>
<ul>
<li>Travere Therapeutics 在鼓舞人心的數據後仍在上升</li>
</ul>
<p>幾家對沖基金最近增加或減少了對 TVTX 的持股。First Horizon Corp 在第三季度購買了價值約 36,000 美元的 Travere Therapeutics 新股份。Raymond James Financial Inc.在第二季度購買了價值約 33,000 美元的 Travere Therapeutics 新頭寸。Mirae Asset Global Investments Co. Ltd.在第四季度將其在 Travere Therapeutics 的持股增加了 26.2%。Mirae Asset Global Investments Co. Ltd.現在擁有 4,348 股公司股票，價值 166,000 美元，此前在此期間又購買了 902 股。Headlands Technologies LLC 在第二季度購買了價值約 73,000 美元的 Travere Therapeutics 新股份。最後，Wealth Enhancement Advisory Services LLC 在第四季度購買了價值約 224,000 美元的 Travere Therapeutics 新股份。</p>
<h2>分析師的升級和降級</h2>
<p>幾家研究公司最近對 TVTX 發表了評論。Weiss Ratings 在 1 月 21 日（星期三）的研究報告中重申了對 Travere Therapeutics 股票的 “賣出（e+）” 評級。Zacks Research 在 11 月 12 日（星期三）的研究報告中將 Travere Therapeutics 的股票評級從 “強力買入” 下調至 “持有”。HC Wainwright 在 11 月 28 日（星期五）的研究報告中重申了 “買入” 評級，並設定了 47.00 美元的目標價。Guggenheim 在 1 月 14 日（星期三）的研究報告中重申了 “買入” 評級，並對 Travere Therapeutics 的股票設定了 49.00 美元的目標價。最後，Wall Street Zen 在 12 月 13 日（星期六）的報告中將 Travere Therapeutics 的評級從 “買入” 升級為 “強力買入”。十二位投資分析師對該股票給予了買入評級，三位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，Travere Therapeutics 的共識評級為 “適度買入”，共識目標價為 38.86 美元。</p>
<p><strong>查看我們關於 TVTX 的最新報告</strong></p>
<h2>關於 Travere Therapeutics</h2>
<p>（獲取免費報告）</p>
<p>Travere Therapeutics, Inc.（納斯達克：TVTX）是一家總部位於加利福尼亞州聖地亞哥的生物製藥公司，致力於開發和商業化針對罕見腎臟和遺傳疾病的療法。公司的使命是通過關注影響小型患者羣體的疾病，解決治療選擇有限的疾病的未滿足需求。Travere 結合了研究、開發和商業能力，將創新藥物推向市場。</p>
<p>公司的主要產品是 sparsentan，這是一種雙重內皮素 - 血管緊張素受體拮抗劑，已獲得美國的加速批准。</p>
<h2>瞭解更多</h2>
<ul>
<li>我們更看好的五隻股票比 Travere Therapeutics 更好</li>
<li>家族信託如何幫助保護您的財富</li>
<li>請勿刪除，立即閲讀</li>
<li>新法律：國會批准數字美元的設立？</li>
<li>用這 4 個簡單步驟 “防止” 您的銀行賬户受到影響</li>
<li>一項價值數萬億的美國 “出生權” 索賠 - 靜悄悄地激活</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFZUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFZUWA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>您現在應該投資 1,000 美元於 Travere Therapeutics 嗎？</h2>
<p>在您考慮 Travere Therapeutics 之前，您需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 Travere Therapeutics 並不在名單上。</p>
<p>雖然 Travere Therapeutics 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

TVTX

<p>Travere Therapeutics 首席執行官 Eric Dube 出售了 8,135 股公司股票，交易金額為 244,131.35 美元，平均價格為 30.01 美元，減少了 1.90% 的持股比例。出售後，他持有 419,173 股，價值約為 1258 萬美元。該交易已向美國證券交易委員會（SEC）披露。Travere 的股票交易價格為 30.03 美元，過去一年價格區間為 12.91 至 42.13 美元。公司報告的季度收入同比增長 162.1%，達到 1.6486 億美元，每股收益（EPS）為 0.28 美元，超出預期。分析師維持 “適度買入” 的共識評級，目標價格為 38.86 美元</p>

<p>Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) CEO Eric Dube sold 8,135 shares of the company's stock in a transaction dated Friday, January 23rd. The shares were sold at an average price of $30.01, for a total transaction of $244,131.35. Following the completion of the transaction, the chief executive officer owned 419,173 shares in the company, valued at $12,579,381.73. This trade represents a 1.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.</p>
<div class="lb-trans"><p>Travere Therapeutics, Inc.（納斯達克代碼：TVTX - 獲取免費報告）首席執行官 Eric Dube 於 1 月 23 日（星期五）出售了 8,135 股公司股票。股票的平均售價為 30.01 美元，總交易額為 244,131.35 美元。交易完成後，首席執行官持有公司 419,173 股股票，價值為 12,579,381.73 美元。此次交易代表其持股比例減少了 1.90%。該交易已在向美國證券交易委員會（SEC）的備案中披露，相關信息可通過此鏈接獲取。</p>
</div><p>Get <strong>Travere Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Travere Therapeutics</strong> 的提醒：</p>
</div><h2>Travere Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>Travere Therapeutics 價格表現</h2>
</div><ul>
<li>3 Under-the-Radar Healthcare Companies</li>
</ul>
<div class="lb-trans"><ul>
<li>3 家不為人知的醫療公司</li>
</ul>
</div><p>NASDAQ:TVTX traded up $0.09 during mid-day trading on Tuesday, reaching $30.03. 1,424,711 shares of the company's stock were exchanged, compared to its average volume of 2,922,582. Travere Therapeutics, Inc. has a one year low of $12.91 and a one year high of $42.13. The company has a debt-to-equity ratio of 4.23, a current ratio of 2.75 and a quick ratio of 2.71. The business's fifty day simple moving average is $34.58 and its two-hundred day simple moving average is $27.12.</p>
<div class="lb-trans"><p>在週二的午盤交易中，納斯達克：TVTX 上漲 0.09 美元，達到 30.03 美元。公司股票交易量為 1,424,711 股，而其平均交易量為 2,922,582 股。Travere Therapeutics, Inc. 的一年最低價為 12.91 美元，一年最高價為 42.13 美元。該公司的債務與股本比率為 4.23，流動比率為 2.75，速動比率為 2.71。該公司的 50 日簡單移動平均線為 34.58 美元，200 日簡單移動平均線為 27.12 美元。</p>
</div><p>Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last announced its earnings results on Thursday, October 30th. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.31) by $0.59. Travere Therapeutics had a negative net margin of 20.32% and a negative return on equity of 178.68%. The firm had revenue of $164.86 million for the quarter, compared to analyst estimates of $106.09 million. During the same quarter in the prior year, the business posted ($0.70) EPS. The business's revenue was up 162.1% compared to the same quarter last year. Analysts forecast that Travere Therapeutics, Inc. will post -1.4 earnings per share for the current year.</p>
<div class="lb-trans"><p>Travere Therapeutics（納斯達克：TVTX - 獲取免費報告）最近於 10 月 30 日（星期四）公佈了其財報。公司報告本季度每股收益（EPS）為 0.28 美元，超出分析師一致預期的（0.31 美元）0.59 美元。Travere Therapeutics 的淨利潤率為-20.32%，股本回報率為-178.68%。該公司本季度的收入為 1.6486 億美元，而分析師預期為 1.0609 億美元。去年同期，該公司的每股收益為（0.70 美元）。與去年同期相比，該公司的收入增長了 162.1%。分析師預測 Travere Therapeutics, Inc.在當前年度的每股收益將為-1.4 美元。</p>
</div><h2>Institutional Investors Weigh In On Travere Therapeutics</h2>
<div class="lb-trans"><h2>機構投資者對 Travere Therapeutics 的看法</h2>
</div><ul>
<li>Travere Therapeutics Still On The Rise After Encouraging Data</li>
</ul>
<div class="lb-trans"><ul>
<li>Travere Therapeutics 在鼓舞人心的數據後仍在上升</li>
</ul>
</div><p>Several hedge funds have recently added to or reduced their stakes in TVTX. First Horizon Corp bought a new stake in shares of Travere Therapeutics in the 3rd quarter valued at about $36,000. Raymond James Financial Inc. bought a new position in shares of Travere Therapeutics in the 2nd quarter worth approximately $33,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Travere Therapeutics by 26.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,348 shares of the company's stock worth $166,000 after buying an additional 902 shares during the period. Headlands Technologies LLC bought a new stake in shares of Travere Therapeutics in the second quarter worth about $73,000. Finally, Wealth Enhancement Advisory Services LLC purchased a new stake in Travere Therapeutics in the 4th quarter worth about $224,000.</p>
<div class="lb-trans"><p>幾家對沖基金最近增加或減少了對 TVTX 的持股。First Horizon Corp 在第三季度購買了價值約 36,000 美元的 Travere Therapeutics 新股份。Raymond James Financial Inc.在第二季度購買了價值約 33,000 美元的 Travere Therapeutics 新頭寸。Mirae Asset Global Investments Co. Ltd.在第四季度將其在 Travere Therapeutics 的持股增加了 26.2%。Mirae Asset Global Investments Co. Ltd.現在擁有 4,348 股公司股票，價值 166,000 美元，此前在此期間又購買了 902 股。Headlands Technologies LLC 在第二季度購買了價值約 73,000 美元的 Travere Therapeutics 新股份。最後，Wealth Enhancement Advisory Services LLC 在第四季度購買了價值約 224,000 美元的 Travere Therapeutics 新股份。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師的升級和降級</h2>
</div><p>A number of research firms recently commented on TVTX. Weiss Ratings reaffirmed a &#34;sell (e+)&#34; rating on shares of Travere Therapeutics in a research note on Wednesday, January 21st. Zacks Research cut shares of Travere Therapeutics from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Wednesday, November 12th. HC Wainwright reiterated a &#34;buy&#34; rating and set a $47.00 price target on shares of Travere Therapeutics in a research report on Friday, November 28th. Guggenheim reiterated a &#34;buy&#34; rating and issued a $49.00 price target on shares of Travere Therapeutics in a research note on Wednesday, January 14th. Finally, Wall Street Zen upgraded Travere Therapeutics from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a report on Saturday, December 13th. Twelve investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Travere Therapeutics has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $38.86.</p>
<div class="lb-trans"><p>幾家研究公司最近對 TVTX 發表了評論。Weiss Ratings 在 1 月 21 日（星期三）的研究報告中重申了對 Travere Therapeutics 股票的 “賣出（e+）” 評級。Zacks Research 在 11 月 12 日（星期三）的研究報告中將 Travere Therapeutics 的股票評級從 “強力買入” 下調至 “持有”。HC Wainwright 在 11 月 28 日（星期五）的研究報告中重申了 “買入” 評級，並設定了 47.00 美元的目標價。Guggenheim 在 1 月 14 日（星期三）的研究報告中重申了 “買入” 評級，並對 Travere Therapeutics 的股票設定了 49.00 美元的目標價。最後，Wall Street Zen 在 12 月 13 日（星期六）的報告中將 Travere Therapeutics 的評級從 “買入” 升級為 “強力買入”。十二位投資分析師對該股票給予了買入評級，三位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，Travere Therapeutics 的共識評級為 “適度買入”，共識目標價為 38.86 美元。</p>
</div><p><strong>View Our Latest Report on TVTX</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 TVTX 的最新報告</strong></p>
</div><h2>About Travere Therapeutics</h2>
<div class="lb-trans"><h2>關於 Travere Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Travere Therapeutics, Inc NASDAQ: TVTX is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company's mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.</p>
<div class="lb-trans"><p>Travere Therapeutics, Inc.（納斯達克：TVTX）是一家總部位於加利福尼亞州聖地亞哥的生物製藥公司，致力於開發和商業化針對罕見腎臟和遺傳疾病的療法。公司的使命是通過關注影響小型患者羣體的疾病，解決治療選擇有限的疾病的未滿足需求。Travere 結合了研究、開發和商業能力，將創新藥物推向市場。</p>
</div><p>The company's lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.</p>
<div class="lb-trans"><p>公司的主要產品是 sparsentan，這是一種雙重內皮素 - 血管緊張素受體拮抗劑，已獲得美國的加速批准。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Travere Therapeutics</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
<li>Do not delete, read immediately</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
<li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li>
<li>A U.S. “birthright” claim worth trillions - activated quietly</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Travere Therapeutics 更好</li>
<li>家族信託如何幫助保護您的財富</li>
<li>請勿刪除，立即閲讀</li>
<li>新法律：國會批准數字美元的設立？</li>
<li>用這 4 個簡單步驟 “防止” 您的銀行賬户受到影響</li>
<li>一項價值數萬億的美國 “出生權” 索賠 - 靜悄悄地激活</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFZUWA" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=TVTX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Travere Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>您現在應該投資 1,000 美元於 Travere Therapeutics 嗎？</h2>
</div><p>Before you consider Travere Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考慮 Travere Therapeutics 之前，您需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Travere Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 Travere Therapeutics 並不在名單上。</p>
</div><p>While Travere Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Travere Therapeutics 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Travere Therapeutics（NASDAQ:TVTX）的首席執行官出售了價值 244,131.35 美元的股票